Long-term impact of infant immunization on hepatitis B prevalence: a systematic review and meta-analysis

Kate Whitford, Bette Liu, Joanne Micallef, J Kevin Yin, Kristine Macartney, Pierre Van Damme & John M Kaldor

Objective To conduct a systematic review and meta-analysis of the long-term impact of infant vaccination on the prevalence of hepatitis B virus (HBV) infection at the population level.

Methods We searched online databases for articles reporting comparisons between population cohorts aged ≥ 15 years who were exposed or unexposed to infant HBV immunization programmes. We categorized programmes as universal or targeted to infants whose mothers were positive for hepatitis B surface antigen (HBsAg). We included studies reporting prevalence of hepatitis B core antibody (HBCAb), HBsAg, or both. We evaluated the quality of the study methods and estimated the relative reduction in the prevalence of infection.

Findings Of 26 studies that met the inclusion criteria, most were from China (20 studies). The prevalence of HBV infection in unvaccinated and universally vaccinated cohorts ranged from 0.6% (116 of 20,305 people) to 16.3% (60/367) and from 0.3% (1/300) to 8.5% (73/857), respectively. Comparing cohorts with universal vaccination to those without vaccination, relative prevalences were 0.24 (95% confidence interval, CI: 0.16–0.35) for HBsAg and 0.23 (95% CI: 0.17–0.32) for HBCAb. For populations with targeted vaccination, relative prevalences were 0.32 (95% CI: 0.24–0.43) and 0.33 (95% CI: 0.23–0.45), respectively.

Conclusion The residual burden of infection in cohorts offered vaccination suggests that longer-term evaluations of vaccination coverage, timeliness and other aspects of programme quality are needed. As HBV-vaccinated infant cohorts reach adulthood, ongoing analysis of prevalence in adolescents and young adults will ensure that elimination efforts are on track.

Abstracts in العربية, 中文, Français, Русский and Español at the end of each article.

Introduction

Infection with the hepatitis B virus (HBV) is a major global cause of ill health that particularly affects low- and middle-income countries. An estimated 257 million people have chronic HBV infection, and 686,000 deaths occur annually due to long-term complications including liver cirrhosis and hepatocellular carcinoma, a number that is projected to increase. 1,2 Most chronic infection is acquired in infancy or early childhood, primarily through mother-to-child transmission. 3,4 Exposure later in life, through sexual intercourse or blood contact, can also lead to chronic infection but more frequently results in viral clearance and immunity.

Vaccines against HBV infection are highly effective. A plasma-derived vaccine, first used in a national infant immunization programme in 1984, 5 was gradually replaced by recombinant vaccines, which can be manufactured at greater scale. 6 The global recommended schedule is a dose at birth, ideally within 24 hours, followed by two to three doses at monthly intervals. 7

A few countries have reported declines in the prevalence of HBV infection following the implementation of infant vaccination programmes, 8,9 and declining incidence of liver cancer in children and young adults. 10–14 The World Health Organization’s (WHO’s) Member States aspire to the goal of global elimination of HBV infection and its consequences, with the central strategy being infant vaccination programmes to achieve direct and herd protection. 15 WHO has set an elimination target of a 90% reduction in prevalence by 2030, 16 and specified two primary target indicators: cumulated incidence of HBV infection in children aged 5 years; and deaths from hepatocellular carcinoma, cirrhosis and chronic liver diseases attributable to HBV infection. 17

Although these two indicators effectively represent programme goals, neither are straightforward to monitor in a consistent way over time. Incidence in 5-year-olds is estimated through surveys that require the collection of specimens from a representative sample, which can be difficult to obtain in this age group. 9 Cause-specific mortality is difficult to measure reliably, particularly in countries with constrained resources. It could take decades for mortality data to fully reflect vaccine-related improvements, due to the long latency of chronic HBV infection in the causation of liver disease.

Prevalence of infection in the wider population is more straightforward to measure and is an earlier and more specific indicator of impact of immunization programmes than measuring prevalence in 5-year-olds alone. Population prevalence is also the core indicator recommended as the first priority by WHO. 17 With infant vaccination now in place for several decades in several countries, it is timely to consider how well it is achieving reductions in HBV infection. This is particularly important as vaccinated generations enter adulthood, a period of higher risk of exposure through sexual activity, 18 and become the potential source of transmission to the next generation. We therefore conducted a systematic review and meta-analysis of studies assessing changes in the prevalence
of HBV markers in populations offered universal or targeted infant immunization at least 15 years before.

Methods

This review was registered and conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Registration is available at: http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017060309 (the checklist is available from the corresponding author).

Search strategy

We searched the online databases of Embase®, MEDLINE®, Web of Science and LILACS to January 2017. The search terms used were: “hepatitis B” AND (“vaccination” OR “mass vaccination” OR “immunization” OR “immunization programmes”) AND (“adolescent” OR “adult”). The search was supplemented by manual searches of reference lists of articles for additional studies.

Inclusion criteria

We included any study addressing the long-term impact of an infant hepatitis B vaccine programme at a population level if it satisfied the following criteria: (i) HBV infection status, as defined by hepatitis B core antibody (HBcAb) or hepatitis B surface antigen (HBsAg) status (or both), was assessed and reported in the study population; (ii) the study population, or a specified subgroup for which data were reported separately, was aged ≥ 15 years at the time when HBV infection status was assessed; (iii) the study population, or a specified subgroup meeting criterion ii, included a cohort not offered vaccination through an infant programme (referred to here as the unvaccinated cohort); and (iv) the study population, or a specified subgroup meeting criterion ii, included a cohort offered vaccination through an infant programme (referred to as the vaccinated cohort).

We categorized infant vaccination programmes as either universal, if hepatitis B vaccine was reported as being available to all newborns; or targeted, if vaccine was available to infants born to women screening positive for chronic HBV infection or to women at high risk for some other reason. In some countries, catch-up vaccination programmes were made available to children born a few years before implementation of universal infant vaccination. In these settings, cohorts classified as targeted may have been involved in both a targeted vaccination programme and a catch-up programme.

The primary outcomes of interest were the serological prevalences of (i) HBsAg, which defines chronic HBV infection, and (ii) HBcAb, which defines past, cleared HBV infection in people who are negative for HBsAg.

Two authors independently reviewed the abstracts of the studies identified by the search strategy for studies that met the inclusion criteria. Chinese language articles were translated by a third author to determine if they met the inclusion criteria. The full texts of articles that appeared to be relevant were reviewed by the two authors independently for inclusion. If the same cohort of individuals appeared to have been included in more than one publication, we contacted the authors of the articles to define overlap and avoid duplication.

Variables extracted

We extracted the following study variables for each eligible study, if available: study design, location (country and region); study period; participants’ age and sex distribution; vaccine programme coverage as reported in the article, including coverage of timely birth dose; number of participants in unvaccinated and vaccinated cohorts; and the number positive for HBsAg and/or HBcAb by serology testing in each cohort. We contacted the authors of the articles if data were unavailable in the original publication.

Quality assessment

In addition to data extraction, two authors separately reviewed the quality of each study using an adapted Cochrane method.20 We considered whether studies had addressed potential confounding variables, used a repeatable sampling frame and calculated a response rate. We also judged whether there was potential for bias through assessment of the serological markers, selective reporting of data or the representativeness of populations surveyed.29

Statistical analyses

We classified studies according to outcome measures (prevalence of HBsAg, HBcAb or both) and whether they reported on universal or targeted infant vaccination programmes. We calculated the relative prevalence (RP) and corresponding 95% confidence intervals (CI) as the ratio of the prevalence in vaccinated and unvaccinated cohorts within each study. Meta-analyses were performed by pooling across studies using the Mantel–Haenszel method. We assessed statistical heterogeneity using I², with a value of > 30% as the cut-off.20 A fixed-effects model was used when there was no significant heterogeneity and a random-effects model otherwise. Publication bias was evaluated visually with a funnel plot. We also conducted separate meta-analyses restricted to studies in which the comparisons involved subjects of the same age, and to determine if effects differed by HBsAg prevalence (< 10% versus ≥ 10%) in the unvaccinated cohort or by geographical location. All analyses were conducted using RevMan version 5.3 (Review Manager, The Cochrane Collaboration, Copenhagen, Denmark).

Results

The electronic search yielded 5781 unique articles which we screened for inclusion (Fig. 1). Of these, we assessed 114 full-text articles for eligibility and excluded 88 that were ineligible for various reasons. As three publications21–23 reported on the same subject group in overlapping study periods, only data from the most recent article was included.21

Study characteristics

Of the 26 studies that met the inclusion criteria (Table 1),21,24–48 most were from Taiwan, China (14 articles),21,24–26,29,31–35,37,45,47 six from mainland China,26,40,41,44,46,48 two each from the Gambia30,43 and Italy,27,43 and one each from Australia,8 Fiji,40 The number of study participants aged 15 years or older varied substantially; from 2593 to 738 19540 (median: 3776). Eleven studies included both targeted and universal vaccination cohorts,21,22,24,25,27,28,29,31,32,34,35,37–39,47 four studies included a targeted vaccination cohort only,21,22,25,47 while 11 studies had only a universal vaccination cohort.21,22,24,25,27,28,31,32,34,35,47 In virtually all studies, unvaccinated cohorts were born in years before the implementation of the newborn vaccination programme or had passed the qualifying age at the time of implementation of catch-up programmes (or both).
Twenty studies used a single cross-sectional seroprevalence survey design,23,25,26,28–31,33,34,45,46 four involved two or more cross-sectional seroprevalence survey time points,31,32,35,39 and two were per-protocol analyses of a cluster randomized trial.43,46 Participants included university entrants,21,25,26,32,40 hospital outpatients,42 members of population-based cohorts,27,30,37,41,43,46 and participants in health screening.46 Some studies involved participants from more than one source.29,30,32,34,36,38,45,47

Study quality
Few studies reported on participation rates for serological testing in the target populations. Those that did were conducted in institutional settings and participation rates were very high. Two studies restricted recruitment to those whose immunization history was recorded.30,43 Potentially confounding variables were reported in a minority of studies, and were generally confined to age, sex and region. The sampling methods appeared to be repeatable in studies based in institutions or on recruitment of blood donors, but was not clear for the other studies. There was no evidence of bias in the strategies used for serological testing or in the data selected for presentation in reports. Generalizability to wider regional or national populations was not addressed in any of the studies.

Prevalence of HBV markers
We analysed 21 studies reporting on HBsAg prevalence in populations exposed to universal vaccination compared with those given no vaccination (Fig. 2). The prevalence in the universally vaccinated cohorts ranged from 0.3% to 8.5% (median: 2.0%). The prevalence of HBsAg in the corresponding no vaccination cohorts were substantially higher, ranging from 0.6% to 16.3% (median: 9.8%). All except one study45 reported a decrease in HBsAg prevalence; the combined RP in vaccinated populations was 0.24 (95% CI: 0.16–0.35; Fig. 2). Among 15 studies that reported on HBsAg in a targeted vaccination cohort (Fig. 3), prevalences ranged from 0.6% to 11.4% (median: 3.2%), compared with a range of 3.5% to 16.3% (median: 10.9%) in the corresponding no vaccination cohorts, leading to a combined RP of 0.32 (95% CI: 0.24–0.43; Fig. 3). Highly significant statistical heterogeneity between studies was found in the meta-analyses of HBsAg prevalence in studies comparing both universal and targeted vaccination with unvaccinated cohorts (I² = 98%, P < 0.001 and I² = 89%, P < 0.001, respectively). We therefore used random-effects models to estimate combined RPs and CIs.

For the corresponding analyses of HBcAb prevalence, there were 13 studies that reported data from a universal vaccination cohort (Fig. 4), and nine that reported on targeted vaccination (Fig. 5). The prevalence of HBcAb in the corresponding no vaccination cohorts ranged from 1.2% to 72.1% (median: 20.3%) and from 1.2% to 43.9% (median: 22.0%), respectively. In vaccinated cohorts, prevalences were between 0.5% to 27.9% (median: 4.3%) for universal vaccination cohorts and 0.3% to 11.3% (median: 7.4%) in targeted vaccination cohorts. The summary RPs for HBcAb prevalence were 0.23 (95% CI: 0.17–0.32) for universal and 0.33 (95% CI: 0.23–0.45) for targeted vaccination. As with the HBsAg analyses, we used random-effect models for estimates and CI due to the highly significant heterogeneity.

Funnel plots for each of the four analyses were symmetrical around the combined RPs (Fig. 6).

Coverage
A birth dose of vaccine, either within 24 hours or at birth, was included in the vaccination schedule for all studies except one from Italy,27 where birth dose was only included in the schedule for targeted vaccination. The main parameter used for coverage was administration of three doses of HBV vaccine. There was limited information on coverage for vaccinated cohorts. Five studies used self-reporting, and found coverage ranging from 55.9% (7 700 of 13 765 people) to over 98% (872/878 people).23,25,26,37,45 Two cohort studies were able to verify the vaccination status of the entire vaccinated group.40,43 One study reported 76.1% (842/1107 people) coverage of the third vaccine dose overall, but 34.5% (35/99 people) for those older than 15 years in the universal vaccination cohort and 19.0% (10/53 people) in the targeted vaccination cohort.27

Only one study reported on timeliness of the birth dose, stating that 65 of 215 participants (30.2%) who had received the full schedule received their first dose within 24 hours.46

While some studies reported on coverage at a national or regional level, coverage was not always specified for the age group included in the review and numerators and denominators were not stated. Overall coverage of universal vaccination in Taiwan, China, as cited by some studies, was generally high, ranging from 86.9 to 98.0%.46,53,54,55,56 In Italy coverage was cited in the paper to have been 63% in 1991 increasing to 99% in some regions by 1996.54 In mainland China, studies cited coverage ranging from 30% in the earlier years of the vaccination programme to 99.9% in 2010.50,51 In the Australian study, coverage among residents of remote indigenous communities was cited to be 90%.52

Fig. 1. Flowchart of selection of studies for the meta-analysis of the long-term impact of hepatitis B virus immunization programmes

8199 records identified through database searching
2 additional records identified through other sources
5782 records screened after duplicates removed
114 full-text articles assessed for eligibility
26 studies included in qualitative synthesis and meta-analysis
88 full-text articles excluded:
- no participants aged 15 years or older (n = 48)
- no unvaccinated cohort (n = 17)
- study was a review (n = 5)
- other reasons (n = 18)

Bull World Health Organ 2018;96:484–497 doi: http://dx.doi.org/10.2471/BLT.17.205153
### Table 1. Summary of studies included in the meta-analysis of the long-term impact of hepatitis B virus immunization programmes

| Reference          | Location                          | Population                                | Study design                                          | Study period | Study sample, no. | Sex, % | Vaccination programme | Age of cohorts, years | HBsAg prevalence, %, by vaccination cohort |
|--------------------|-----------------------------------|-------------------------------------------|------------------------------------------------------|--------------|-------------------|--------|------------------------|------------------------|---------------------------------------------|
| Lin et al., 2003   | Hualien and Eastern Taiwan, China | High-school students                     | Repeated cross-sectional seroprevalence surveys     | 1991–2001    | 10,194            | M: 54; F: 46   | Targeted               | Unvaccinated: 15; targeted: 15            | 12.1 4.1 NA                                |
| Chang et al., 2007 | Taipei, China                     | Students entering university              | Cross-sectional seroprevalence survey               | 2003–2004    | 7,592             | M: 53; F: 47   | Targeted               | Overall mean: 19.8 (range: 16.1–54.2)  | 7.4 2.2 NA                                  |
| Chen et al., 2007  | Central Taiwan, China             | Medical students attending university     | Cross-sectional seroprevalence survey               | 2000–2003    | 4,575             | M: 47; F: 53   | Targeted               | Overall mean: 18.7 (range: 17–38)      | 8.0 3.6 NA                                  |
| Da Villa et al., 2007 | Afragola, Italy                 | Residents of Afragola, Italy             | Repeated cross-sectional seroprevalence surveys     | 1978 and 2006 | 660b             | M: 51; F: 49   | Universal              | Unvaccinated: 15–20; universal: 15–20   | 10.3 NA 0.3                                |
| Ni et al., 2007    | Taipei city, Taiwan, China       | Participants recruited from schools, institutes, or workplaces | Cross-sectional seroprevalence survey               | 2004         | 1,142             | M, F          | Targeted, Universal    | Unvaccinated: 20–30; targeted: 18–19; universal: 15–17 | 10.9 2.1 1.5                                |
| Su et al., 2007    | Northern Taiwan, China           | New entry university students             | Cross-sectional seroprevalence survey               | 2005         | 1,969             | M, F          | Targeted, universal    | Unvaccinated: 21+ Targeted: 19–21; universal: 17–19 | 8.7 3.2 1.7                                |
| Van der Sande et al., 2007 | Gambia                        | Participants in the Gambia Hepatitis Intervention Study | Cross-sectional seroprevalence survey               | 2004         | 1,000             | M: 45; F: 55   | Universal              | Unvaccinated: 15; universal: 15          | 12.1 NA 0.5                                |
| Lin et al., 2008   | Southern Taiwan, China           | Pregnant Taiwanese women receiving prenatal examinations | Cross-sectional seroprevalence survey               | 1996–2005    | 10,327            | F: 100        | Targeted, universal    | Not reported                                   | 15.7 11.4 3.1                                |
| Lu et al., 2009    | Central and northern Taiwan, China | College and private university students | Repeated cross-sectional seroprevalence surveys     | 2000–2007    | 4,193             | M: 28; F: 72   | Targeted, universal    | Unvaccinated: 18; targeted: 15–18; universal: 15–18 | 11.6 3.5 1.15                                |
| Sun et al., 2009   | Taiwan, China                    | Consecutive HIV-negative persons seeking health check-up | Cross-sectional seroprevalence survey               | 2004–2007    | 2,594c            | M: 69; F: 31   | Universal              | Overall median: 38 (range 16–94)  | 15.5 NA 8.5                                |
| Chen et al., 2011  | 21 universities across Taiwan, China | New entry university students             | Repeated cross-sectional seroprevalence surveys     | 1995–2009    | 10,1584           | M: 53; F: 47   | Targeted, universal    | Overall mean: 18.5 (range 17.8–20.7) | 11.8 2.3 1.9                                |

(continues...)
| Reference | Location | Population | Study design | Study period | Study sample, no. | Sex, % | Vaccination programme | Age of cohorts, years | HBsAg prevalence, %, by vaccination cohort^a |
|-----------|----------|------------|--------------|--------------|-------------------|-------|------------------------|---------------------|-----------------------------------|
| Chu et al., 2011 | Northern Taiwan, China | Clinic attendees and university students | Cross-sectional seroprevalence survey | 2008 | 2515 | M: 60; F: 40 | Targeted, universal | Unvaccinated, mean: 41.1; targeted, mean: 22.8; universal, mean: 18.6 | 163 | 5.2 | 2.8 |
| Lin et al., 2011 | Central Taiwan, China | Undergraduate and graduate students entering university | Cross-sectional seroprevalence survey | 2005 | 1677 | M: P | Targeted, universal | Unvaccinated: 21+; targeted: 19–21; universal: 17–19 | 11.7 | 1.6 | 1.7 |
| Shen et al., 2011 | Long An county, China | Residents of five villages in Long An county | Cross-sectional seroprevalence survey | 2005 | 3440 | M: F | Universal | Unvaccinated: 20–94; targeted: 15–19 | 7.1 | NA | 5.5 |
| Lai et al., 2012 | Northern, central, southern and eastern Taiwan, China | Participants recruited into epidemiology study for vaccine-preventable diseases | Cross-sectional seroprevalence survey | 2007 | 259 | M: P | Targeted, universal | Unvaccinated: 23+; targeted: 21–23; universal: 18–21 | 9.3 | 9.4 | 2.0 |
| Liu et al., 2012 | Northern Territory, Australia | Aboriginal women giving birth in public hospitals | Cross-sectional seroprevalence survey | 2005–2010 | 5678 | F: 100 | Targeted, universal | Unvaccinated mean: 27.2; universal mean: 18.0 | 3.5 | 2.2 | 0.8 |
| Ni et al., 2012 | Taipei city, Taiwan, China | Participants recruited from schools, institutes or workplaces | Cross-sectional seroprevalence survey | 2009 | 1681 | M: P | Targeted, universal | Unvaccinated: 26–29; targeted: 24–25; universal: 15–23 | 8.2 | 4.5 | 1.2 |
| Yang et al., 2012 | Zhejiang province, China | Participants of province-wide health examination plan | Cross-sectional seroprevalence survey | 2010 | 738195 | M: 41; F: 59i | Universal | Unvaccinated: 20+; universal: 15–19 | 7.2 | NA | 3.5 |
| Zhang et al., 2012 | Shanghai, China | Infants born in 1986 from Huang Pu district, Shanghai | Cross-sectional seroprevalence survey | 2007–2009 | 1204 | M: P | Targeted | 21–30 | 14.2 | 0.6 | NA |
| Boccalini et al., 2013 | Tuscany, Central Italy | Hospital outpatients in Tuscany | Cross-sectional seroprevalence survey | 2009 | 762 | M: 50; F: 50 | Universal | Unvaccinated: 31–50; universal: 21–30 | NA | NA | NA |
| Peto et al., 2014 | Gambia | Participants of the Gambia Hepatitis Intervention Study born 1986–1990 | Per-protocol analysis of cluster randomized trial | 2007–2008 | 753 | M: P | Universal | Unvaccinated: 17–22; universal: 17–22 | 12.4 | NA | 2.2 |
| Liao et al., 2014 | Guangxi Zhuang autonomous region, China | Students from one college in Liuzhou city | Cross-sectional seroprevalence study | 2009 | 392 | M: 18; F: 82 | Universal | Unvaccinated: 31–50; universal: 21–30 | 12.0 | NA | 5.3 |

(continues . . .)
| Reference | Location | Population | Study design | Study period | Study sample, no. | Sex, % | Vaccination programme | Age of cohorts, years | HBsAg prevalence, %, by vaccination cohort |
|-----------|----------|------------|--------------|--------------|------------------|--------|----------------------|---------------------|----------------------|
| Tsukakoshi et al., 2015 | Fiji | Residents of the central, western and northern health divisions of Fiji | Cross-sectional seroprevalence study | 2008–2009 | 504 | M: 80; F: 20 | Universal | Unvaccinated: 21–49; universal: 16–20 | 3.2 | NA | 5.7 |
| Chen et al., 2016 | Qidong, China | Participants of the Qidong Hepatitis B Intervention Study | Per-protocol analysis of cluster randomized trial | 2013 | 8301 | M; F | Universal | Unvaccinated, mean: 26.5; universal, mean: 25.6 | 9.0 | NA | 2.4 |
| Ni et al., 2016 | Taipei, Taiwan, China | Participants recruited from schools, institutions and workplaces | Cross-sectional seroprevalence survey | 2014 | 3036 | M; F | Targeted, universal | Unvaccinated: 30–50; universal: 15–29 | 7.0 | 3.2 | 0.6 |
| Wang et al., 2016 | Shenzhen, China | Blood donors | Cross-sectional seroprevalence study | 2005–2014 | 118423 | M: 67; F: 33 | Universal | Unvaccinated: 18–22 | 3.89; 0.57 | NA | 3.51; 0.27 |

F: female; HBV: hepatitis B virus; HBsAg: hepatitis B surface antigen; HIV: human immunodeficiency virus; M: male; NA not applicable.

* Targeted refers to infant vaccination programmes in which vaccine was available to infants born to women found on the basis of screening to have chronic HBV infection or determined to be at high risk for some other reason. Universal refers to infant vaccination programmes in which hepatitis B vaccine was reported as being available to all newborns. Unvaccinated refers to cohorts that had no universal or targeted hepatitis B immunization programmes.

* We only included 15–20 years age group from this study.

* Sex distribution not reported in the article for ages ≥ 15 years.

* Region not reported in the article.

* Total sex distribution for participants aged ≥ 15 years.

* Age distribution for all participants included in the article, aged ≥ 0 years.

* We excluded HIV-positive participants from total and calculations.

* Data collected for ages 15–19 years was requested and provided by authors (article only provides data for 0–20 year age group collectively).

* Article reported anti-hepatitis core antibody levels only.

* Article only reported in the article for vaccinated group, age 21–49 years.

* Age range for both first-time and repeat blood donor groups.

* First-time blood donors.

* Repeat blood donors.
Sub-group analyses

We also restricted analyses to the five studies that compared HBsAg prevalence between universally vaccinated and unvaccinated cohorts of the same age (Fig. 7).21,27,30,32,43 The combined RP was 0.12 (95% CI: 0.08–0.19) compared with 0.30 (95% CI: 0.21–0.43) in 16 studies based on comparisons of cohorts at different ages.28,29,31,33–40,44–48

Restricting analyses to those with HBsAg prevalence under 10% in the unvaccinated group yielded 10 studies, all of which assessed HBsAg positivity in cohorts with universal vaccination.29,30,36–40,43,44 The combined RP was 0.34 (95% CI: 0.23–0.52). In comparison, RP was 0.17 (95% CI: 0.12–0.25) across the 11 studies with HBsAg prevalence of at least 10% in the unvaccinated cohort.21,27,28,30–33,43,44

For targeted vaccination cohorts, the RP based on seven studies with HBsAg prevalence under 10% in the corresponding unvaccinated cohorts was 0.42 (95% CI: 0.32–0.56).25,26,29,37–39,47 It was 0.24 (95% CI: 0.16–0.36) in eight studies for which prevalence was above 10% in the unvaccinated cohort.24,26,31,32,34,35,37,41

Restricting analyses to studies from Taiwan, China (11 studies),21,26,29,31–35,37,39,47 for universal vaccination cohorts, the combined RP for protection was 0.17 (95% CI: 0.12–0.24), while for the 10 studies from other countries27,30,36,38,40,43–46,48 the reduction in risk was 0.36 (95% CI: 0.24–0.54). For targeted vaccination, the RP was 0.33 (95% CI: 0.25–0.44) for studies from Taiwan, China (13 studies),21,24,26,28,29,31,32,34,35,37,39,47 with only two such studies from another area.38,41

Discussion

Our meta-analysis of the long-term impact on infection of infant hepatitis B vaccination programmes at the population level focused on long-term impact by restricting the time period to at least 15 years following vaccination. An earlier review of impact did not report a combined estimate and did not specifically focus on long-term impact.49 We found that adolescents and adults in birth cohorts that were offered universal infant vaccination had a 76% lower prevalence of HBV infection and a similar reduction in risk (77%) of HBcAb prevalence compared with cohorts for whom infant vaccine programmes were unavailable. The effect was similar for both higher and lower levels of HBsAg prevalence in the unvaccinated population. The impact of targeted vaccination programmes was slightly lower (68% and 67%, respectively). As a result of overlap in the relevant cohorts, it was not possible to distinguish the effect of these programmes from the impact of catch-up programmes. It was also not possible to separate the direct effect of targeted programmes from herd effects of reduced horizontal transmission, both in vaccinated same-age peers and slightly younger universally vaccinated cohorts.

![Table 1](https://example.com/table1)

**Table 1.** Meta-analysis of the long-term impact of immunization programmes: comparison of universal and unvaccinated cohorts

| Study or subgroup | Year of study | Universal vaccination | Unvaccinated | % weight RP (95% CI) | RP (95% CI) |
|-------------------|---------------|-----------------------|-------------|---------------------|------------|
| Da Vella et al., 2007 | 2006          | 1                      | 300         | 37                  | 0.4        | 0.03 (0.00–0.23) |
| Nie et al., 2007   | 2004          | 98                     | 6,531       | 124                 | 1.34       | 2.2        | 0.14 (0.11–0.18) |
| Sun et al., 2007   | 2004          | 21                     | 1,234       | 44                  | 506        | 0.7        | 0.20 (0.12–0.33) |
| Van der Sande et al., 2007 | 2004    | 3                      | 576         | 51                  | 420        | 0.6        | 0.04 (0.01–0.14) |
| Lin et al., 2008   | 2005          | 3                      | 96          | 1,570               | 10,021     | 0.3        | 0.20 (0.07–0.61) |
| Liu et al., 2009   | 2007          | 38                     | 3,514       | 22                  | 189        | 0.4        | 0.10 (0.06–0.16) |
| Sun et al., 2009   | 2007          | 73                     | 857         | 269                 | 1,737      | 1.9        | 0.55 (0.43–0.70) |
| Chen et al., 2011  | 2009          | 986                    | 51,924      | 4,649               | 39,512     | 55.3       | 0.16 (0.15–0.17) |
| Chu et al., 2011   | 2008          | 48                     | 1,745       | 60                  | 367        | 1.0        | 0.17 (0.12–0.24) |
| Lui et al., 2011   | 2005          | 11                     | 660         | 90                  | 771        | 0.9        | 0.14 (0.08–0.26) |
| Shen et al., 2011  | 2007          | 27                     | 487         | 308                 | 2,923      | 0.9        | 0.53 (0.36–0.77) |
| Liu et al., 2012   | 2007          | 2                       | 9           | 10                  | 107        | 0.1        | 0.22 (0.05–0.96) |
| Liu et al., 2012   | 2010          | 9                       | 1,170       | 75                  | 2,130      | 0.6        | 0.22 (0.11–0.43) |
| Nie et al., 2012   | 2009          | 13                      | 1,105       | 31                  | 378        | 0.5        | 0.14 (0.08–0.27) |
| Yang et al., 2012  | 2010          | 310                     | 8,793       | 52,649              | 72,987     | 13.1       | 0.49 (0.44–0.54) |
| Xiao et al., 2014  | 2009          | 12                      | 226         | 21                  | 166        | 0.3        | 0.42 (0.21–0.83) |
| Peng et al., 2016  | 2008          | 6                       | 278         | 59                  | 475        | 0.5        | 0.17 (0.08–0.40) |
| Tsukakoshi et al., 2015 | 2009    | 7                       | 124         | 12                  | 370        | 0.1        | 0.14 (0.07–0.32) |
| Chen et al., 2016  | 2013          | 105                     | 4,421       | 350                 | 3,880      | 3.9        | 0.26 (0.21–0.33) |
| Ni et al., 2016    | 2014          | 10                      | 1,642       | 84                  | 1,203      | 1.0        | 0.09 (0.05–0.17) |
| Wang et al., 2016a | 2014          | 14                      | 5,113       | 116                 | 20,305     | 0.5        | 0.48 (0.28–0.83) |
| Wang et al., 2016b | 2014          | 2,374                   | 6,963       | 985                 | 25,522     | 1.5        | 0.90 (0.84–0.97) |

**Total**

| NA | 4,171 |
|---|-------|
| NA | 6,156 |
| NA | 7,935 |
| NA | 8,471 |
| NA | 10,961 |

CI: confidence interval; df: degrees of freedom; NA: not applicable; RP: relative prevalence.

a Repeat donor.

b First-time donor.
Our findings are valuable for demonstrating in a systematic way what extent of reductions in prevalence could be expected from infant HBV vaccination programmes. Most countries (184 countries in 2014) have implemented such programmes, but few have so far reported on long-term impact. As cohorts of adolescents and young adults are entering a period of exposure risk through sexual activity, and will become parents of the next generation, it is appropriate to measure prevalence of infection in this age group.18 The similarity between the impact on HBcAb and HBsAg suggests that the vaccine’s mechanism of protection applies equally to preventing infection and...
stopping it from becoming established. Nevertheless, there was still evidence of acquisition of HBV infection in all of the vaccine-eligible populations. The most likely explanation for residual infection is incomplete vaccine coverage or non-timely vaccination.28,37,42,45

Studies have shown that perinatal HBV transmission is higher in infants who received the birth dose late or re-

**Fig. 5.** Relative prevalence of hepatitis B core antibody in the meta-analysis of the long-term impact of immunization programmes: comparison of targeted vaccination and unvaccinated cohorts

| Study or subgroup | Year of study | Total no. | No. positive | Total no. | % weight | RP (95% CI) |
|------------------|---------------|-----------|--------------|-----------|-----------|-------------|
|                   |               |           | No. positive | Total no. |           |             |
| Chang et al., 2007| 2004          | 425       | 283         | 1204      | 17.9      | 0.28 (0.25–0.32) |
| Chen et al., 2007 | 2003          | 145       | 645         | 3146      | 17.7      | 0.49 (0.42–0.59) |
| Ni et al., 2007   | 2014          | 12        | 1442        | 206       | 9.2       | 0.25 (0.12–0.55) |
| Su et al., 2007   | 2015          | 20        | 506         | 134       | 13.8      | 0.30 (0.19–0.47) |
| van der Sande et al., 2007 | 2014  | 106      | 226         | 424       | NA        | Not estimable |
| Chu et al., 2011  | 2008          | 27        | 148         | 137       | 14.7      | 0.18 (0.12–0.26) |
| Liu et al., 2012  | 2007          | 6         | 107         | 47        | 9.0       | 0.26 (0.12–0.56) |
| Ni et al., 2012   | 2009          | 21        | 198         | 57        | 13.4      | 0.70 (0.44–1.13) |
| Ni et al., 2016   | 2014          | 2         | 47          | 1203      | 4.2       | 0.27 (0.07–1.09) |
| Total             | NA            | 12784     | NA          | 8053      | 100.00    | 0.33 (0.23–0.45) |

Heterogeneity: $X^2 = 47.62, df = 7 \ (P < 0.001), I^2 = 85\%$

Test for overall effect: $Z = 6.7 \ (P < 0.001)$

CI: confidence interval; df: degrees of freedom; NA: not applicable; RP: relative prevalence

**Notes:** The figure shows the number of participants positive for the hepatitis B surface antigen and the total number of participants in the cohort being measured. Totals may not equal the total number of participants in Table 1, as only age-eligible participants were included in our analysis.

**Fig. 6.** Funnel plot of publication bias in studies of the prevalence of hepatitis B virus markers in adults

Hepatitis B core antibody: HBcAb; HBsAg: hepatitis B surface antigen; RP: relative prevalence; SE: standard error

**Notes:** The relative prevalence is shown. Visual examination of the plot reveals symmetry of the individual studies to the combined prevalence ratio for the 22 studies.
39% in 2015.\(^4\) The few studies in our systematic review that reported on vaccine coverage recorded highly varying rates. Most of the vaccinated cohorts from the studies in Taiwan, China, were born in the early years of the infant vaccination programme when coverage was lower. The only study reporting on administration of the birth dose within 24 hours, from mainland China, found coverage of 30.2%.\(^54\) No studies reported on the actual timing of the birth dose. Lack of timeliness of the birth dose and inadequate coverage of the full schedule are likely to have contributed to the residual infection that we found in vaccinated cohorts. Further monitoring of more recent cohorts, including reporting of timeliness of the birth dose, is needed to determine the impact of improved coverage on infection rates.

Vaccine failure, primary (no initial immune response) or secondary (waning of immunity), may have been another cause of infections in the vaccinated cohorts.\(^53\) Poor immunological response was demonstrated in reports of both active and cleared HBV infection detected among fully vaccinated people.\(^54\)–\(^56\) HBV prevalence in vaccinated populations could also be attributed to mutations in the HBV S-gene, which can allow the virus to avoid being neutralized by the vaccine-generated antibodies.\(^55\)–\(^57\) However, while they need to be monitored, these mutants probably have little significance at a public health level and are unlikely to be a major cause of prevalence in vaccinated cohorts.\(^58\)

More than half of the studies included in this meta-analysis were from Taiwan, China, reflecting a strong, early commitment to HBV prevention and research in this formerly high-prevalence area. The reduction in HBsAg prevalence was markedly higher for these studies than those in other areas (83% versus 64%). The early attainment of high newborn coverage of hepatitis B vaccine in Taiwan, China, over 95% by 2002,\(^13\) could explain this observation.

The studies we included had limitations. Most were based on a single time-point, and compared people who had received vaccination with those who had not, on the basis of their birth cohort. As these two groups were inevitably of different ages at the time of surveying, it is not possible to remove any effect of age from the comparison. However, it is likely that most chronic infections were acquired in infancy and early childhood, and that prevalence would have been relatively stable in adolescence and adulthood, with at most a slight age-related increase. On the other hand, the estimated reduction in prevalence was 88% for the few studies that compared cohorts of the same age, as opposed to 70% in the single time-point surveys. This finding was surprising, as we might expect that studies comparing younger vaccinees to older unvaccinated cohorts would generate a more favourable estimate if there had been any increase of prevalence with age. However, comparisons involving same-age cohorts may have been affected by other, unknown confounders.

Limitations of the meta-analysis included the considerable heterogeneity in estimated effect sizes, and the statistically dominant role played by a small number of studies that contributed large numbers. Heterogeneity may have been due to differences in study designs, populations and immunization coverage, and to the characteristics identified in our assessment of study quality, such as response rates. Nevertheless all studies except one reported substantially lower HBsAg prevalence in the vaccinated cohort compared with the unvaccinated group, and the one exception reported low coverage in the vaccinated cohort.\(^60\)

Another issue to consider in interpreting the findings is the relatively narrow geographical spread of studies. Although many countries have had historically high prevalence of hepatitis B, particularly in the WHO Western Pacific and African regions,\(^59\) most of the published studies that met our inclusion requirements were from China. Few studies from Africa met the inclusion criteria, so we were unable to separately assess impact in this region, where horizontal transmission is believed to play a greater role of transmission compared with Asian countries where perinatal transmission dominates.\(^60\) Determining the impact of vaccination in African countries would be important, particularly the impact of timely birth dose vaccination on reductions in prevalence in this setting.

With infant HBV vaccination programmes now widely in place, many countries could now evaluate the longer term impact on the prevalence of...
infection. The ideal mechanism for this evaluation is a time-series comparison with observations at regular time-points, from comparable populations. In many countries, an efficient approach is serological testing done routinely in pregnant women or other populations, such as new entrants to university, the military or other institutions. All these populations are likely to be accessible for routine, repeatable monitoring. As identified in our quality assessment, such designs should incorporate repeatable sampling frames, measure participation rates and adjust for potential confounding factors. While prevalence in 5-year-olds provides a more immediate indicator of impact, large representative samples in this age group cannot be easily accessed in many settings.

Our estimated reduction in prevalence is consistent with findings of modelling studies which suggested that routine infant vaccination from birth with global coverage of 90% could prevent 4.3 million new infections from 2015 to 2030, and could prevent 84% of HBV-related deaths in the hypothetical birth cohort from the year 2000. Our findings strongly support the importance of the WHO target of 90% coverage of the hepatitis B vaccine in infancy, as low coverage is a potential contributor to residual HBV prevalence. The evidence presented here shows that elimination is achievable, but still on the far horizon. Analyses of available serological data on HBV prevalence in adolescents and young adults can provide information on gaps in the pathway to elimination that can then be addressed through programmatic measures.

Funding: National Health and Medical Research Council and Australian Government Department of Health.

Competing interests: J Kevin Yin began his involvement in this work when he was at the National Centre in Immunisation Research and Surveillance. He is a current employee of Sanofi Pasteur Australia and New Zealand, a vaccine manufacturer that does not have a hepatitis B vaccine. His involvement in this review is within his capacity of honorary lecturer of the University of Sydney only.

Towards elimination of hepatitis B

Kate Whitford et al.

Systematic reviews

Melanz

Conclusions

The primary objective of this review was to conduct a systematic review and meta-analysis to determine the impact of infant vaccination on the epidemiology of hepatitis B virus (HBV) in children and adolescents, and to estimate the residual burden of hepatitis B in populations that have achieved universal vaccination coverage. The review included studies conducted in countries with high HBV prevalence and with varying levels of vaccination coverage, aiming to establish the evidence base for the evaluation of hepatitis B vaccination programs in low-resource settings.

The review included 13 studies, all conducted in high-prevalence countries, with varying levels of vaccination coverage. The studies included a total of 4,000,000 children, with median age of 10 years at the time of vaccination. The studies assessed the impact of infant vaccination on the incidence of hepatitis B, and on the rate of children with positive hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (HBcAb) at ages 10-18 years.

The review found that infant vaccination with hepatitis B vaccine (HBV) significantly reduced the incidence of hepatitis B in children and adolescents, with a reduction in the prevalence of HBsAg from 0.16% to 0.02% in vaccinated populations compared to unvaccinated populations. The review also found that the impact of infant vaccination was greater in populations with lower coverage, with a reduction in the prevalence of HBsAg from 0.32% to 0.08% in populations with coverage of 40% compared to 60%.

The review also found that infant vaccination with hepatitis B vaccine (HBV) significantly reduced the rate of children with positive hepatitis B core antibody (HBcAb), with a reduction in the prevalence of HBcAb from 0.23% to 0.07% in vaccinated populations compared to unvaccinated populations. The review also found that the impact of infant vaccination was greater in populations with lower coverage, with a reduction in the prevalence of HBcAb from 0.30% to 0.10% in populations with coverage of 40% compared to 60%.

The review concluded that infant vaccination with hepatitis B vaccine (HBV) is an effective strategy for reducing the incidence and prevalence of hepatitis B in children and adolescents, and for reducing the rate of children with positive hepatitis B core antibody (HBcAb). The review also highlighted the importance of maintaining high vaccination coverage to sustain the impact of infant vaccination on the epidemiology of hepatitis B in children and adolescents.

The implications of this review for hepatitis B vaccination programs are that high coverage of infant vaccination with hepatitis B vaccine (HBV) is critical for achieving long-term epidemiological impact, and that maintaining high coverage is essential for sustaining the impact of infant vaccination on the epidemiology of hepatitis B in children and adolescents.

The review also highlighted the importance of monitoring and evaluating the impact of infant vaccination on the epidemiology of hepatitis B in children and adolescents, and for maintaining high coverage to sustain the impact of infant vaccination on the epidemiology of hepatitis B in children and adolescents.

The review concluded that infant vaccination with hepatitis B vaccine (HBV) is an effective strategy for reducing the incidence and prevalence of hepatitis B in children and adolescents, and for reducing the rate of children with positive hepatitis B core antibody (HBcAb). The review also highlighted the importance of maintaining high vaccination coverage to sustain the impact of infant vaccination on the epidemiology of hepatitis B in children and adolescents.
Цель Провести систематический обзор и метаанализ долгосрочного влияния вакцинации младенцев на распространенность вирусного гепатита B (HBV) на уровне популяции.

Методы В онлайн-базах данных авторы провели поиск статей, в которых сообщалось о сопоставлении популяционных когорт, включающих детей в возрасте ≥15 лет, которые ранее были иммунизированы в рамках программ иммунизации младенцев против HBV либо не иммунизированы. Авторы классифицировали программы как универсальные либо направленные на младенцев, у матерей которых был обнаружен положительный результат анализа на поверхностный антиген вируса гепатита B (HBsAg). Авторы также включили исследования, в которых сообщалось о распространенности положительного результата анализа на антиген к капсидному антигену вируса гепатита B (HBcAb) или статуса по HBsAg либо обоих показателей. Была проведена оценка качества методов исследования и относительного снижения распространенности инфекции.

Результаты Из 26 исследований, которые соответствовали критериям включения, большинство было проведено в Китае (20 исследований). Распространенность HBV в невакцинированных и универсально вакцинированных когортах варьировала от 0,6% (116 из 20 305 человек) до 16,3% (60 из 367) и от 0,3% (1/300) до 8,5% (73/857) соответственно. При сравнении когорт с универсальной вакцинацией и без вакцинации относительная распространенность составила 0,24 (95%-й ДИ: 0,16–0,35) для HBsAg и 0,23 (95%-й ДИ: 0,17–0,32) для HBcAb. В популяциях с целенаправленной вакцинацией относительная распространенность составила 0,32 (95%-й ДИ: 0,24–0,43) и 0,33 (95%-й ДИ: 0,23–0,45) соответственно.

Вывод Остаточное бремя инфекции в нескольких когортах, которым была проведена вакцинация, свидетельствует о том, что необходимы долгосрочные оценки охвата вакцинацией, временного охвата и других аспектов качества программы. По мере вакцинации вакцинированных от HBV когорты младенцев постоянный анализ распространенности заболевания среди подростков и молодых людей обеспечит успех усилий по ликвидации этой инфекции.
prevalencia relativa fue del 0.32 (95% IC: 0.24–0.43) y del 0.33 (95% IC: 0.23–0.45), respectivamente.

Conclusion La carga residual de la infección que ofrece la vacunación en diversas cohortes, sugiere que son necesarias las evaluaciones a largo plazo de la cobertura de vacunación, del carácter oportuno y de otros aspectos sobre la calidad del programa. A medida que las cohortes de niños vacunados contra el VHB alcanzan la edad adulta, un análisis continuo de la prevalencia en adolescentes y en jóvenes asegurará que los esfuerzos para su eliminación van por buen camino.

References

1. Global hepatitis report 2017. Geneva: World Health Organization; 2017. Available from: http://apps.who.int/nr/ntdb/stream/handle/10665/255016/9789241565455-eng.pdf;sessionid=94DCC04DE49C875F1851513C14FEEDE5/sequence=1 [cited 2018 May 8].

2. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Jan 10;385(9963):117–71. doi: http://dx.doi.org/10.1016/S0140-6736(14)61682-2 PMID: 25530442.

3. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci. 1993 Aug 23;253(1337):197–201. doi: http://dx.doi.org/10.1098/rspb.1993.0102 PMID: 8397416.

4. Hepatitis B vaccines: WHO position paper – July 2017. Wkly Epidemiol Rec. 2017 07 09(23):369–92. PMID: 28685564.

5. Chen DS, Hsu NH, Sung JL, Hsu TC, Hsu ST, Kuo YP, et al. A mass vaccination program against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA. 1987 May 12;257(19):2597–603. doi: http://dx.doi.org/10.1001/jama.1987.03930190070023 PMID: 3573257.

6. Van Damme PW, Shouval D, Zanetti A. Hepatitis B vaccines. In: Plotkin SA, Orenstein WA, editors. Plotkin's vaccines. 7th ed. Philadelphia: Elsevier; 2017. pp. 342–74.

7. Table 2: Summary of WHO Position Papers – recommended routine immunizations for children [Internet]. Geneva: World Health Organization; 2017. Available from: http://www.who.int/immunization/policy/immunization_tables/en/ [cited 2018 May 8].

8. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of the Qidong hepatitis B intervention study: a cluster randomized trial. PLoS Med. 2014 12 30;11(12):e1001774. doi: http://dx.doi.org/10.1371/journal.pmed.1001774 PMID: 25549238.

9. Wiesen E, Diorditsa S, Li X. Progress towards hepatitis B prevention indicators and framework. Geneva: World Health Organization; 2016. Available from: http://www.who.int/hepatitis/publications/hep-b-c-monitoring-evaluation/en/ [cited 2018 May 8].

10. van Damme PW, Shouval D, Zanetti A. Hepatitis B vaccines. In: Plotkin SA, Orenstein WA, editors. Plotkin's vaccines. 7th ed. Philadelphia: Elsevier; 2017. pp. 342–74.

11. Conclusión Los esfuerzos para su eliminación van por buen camino.
33. Sun HY, Ko WC, Tsai JJ, Lee HC, Liu CE, Wong WW, et al. Seroprevalence of chronic hepatitis B virus infection among Taiwanese human immunodeficiency virus type-1–positive persons in the era of nationwide hepatitis B vaccination. Am J Gastroenterol. 2009 Apr;104(4):877–84. doi: http://dx.doi.org/10.1038/ajg.2008.159 PMID: 19259078

34. Chu FY, Su FH, Cheng SH, Lin YS, Li CY, Chien CC, et al. Hepatitis B surface antigen confirmatory testing for diagnosis of hepatitis B virus infection in Taiwan. J Med Virol. 2011 Sep;83(9):1514–21. doi: http://dx.doi.org/10.1002/jmv.22127 PMID: 21739440

35. Lin YJ, Lan YC, Wan L, TH, Chen DY, Tsai CH, et al. Serological surveillance and IL-10 genetic variants on anti-HBs titers: hepatitis B vaccination 20 years after neonatal immunization in Taiwan. Clin Chim Acta. 2011 Apr 11;412(9-10):766–73. doi: http://dx.doi.org/10.1016/j.cca.2011.01.006 PMID: 21238445

36. Shen LB, Zhang Y, Wang F, Zhang S, Yang JF, Fang KX, et al. Epidemiological changes in hepatitis B prevalence in an entire population after 20 years of the universal HBV vaccination programme. Epidemol Infect. 2011 Aug;139(8):1159–65. doi: http://dx.doi.org/10.1017/S0950268810002827 PMID: 21156099

37. Lai MW, Lin TY, Tsao KC, Huang CG, Hsiao MJ, Liang KH, et al. Increased hepatitis B serologic survey and review of immunization records of children, adolescents and adults in Fiji, 2008–2009. Virol J. 2011;8:163. doi: http://dx.doi.org/10.1186/1471-2334-10-163 PMID: 21653306

38. Liu B, Guthridge S, Li SQ, Markey P, Krause V, McIntyre P, et al. The end of the hepatitis B era? An ecological study of the impact of universal newborn hepatitis B vaccination two decades on. Vaccine. 2012 Nov 26;30(50):7309-14. doi: http://dx.doi.org/10.1016/j.vaccine.2012.09.033 PMID: 23036497

39. Ni YH, Chang MH, Jan CF, Hsu HY, Chen HL, Wu JF, et al. Continuing decrease of the hepatitis B serologic prevalence of newborns and young children from ages 0 to 17 years in Taiwan. Am J Epidemiol. 2011 May 1;173(9):1021–9. doi: http://dx.doi.org/10.1093/aje/kwr213 PMID: 21480610

40. Yang SC, Wang B, Chen PY, Su CB, Deng M, Yao J, et al. Effectiveness of HBV vaccination in infants and prediction of HBV prevalence trend under new vaccination plan: findings of a large-scale investigation. PloS One. 2012;7(10):e47808. doi: http://dx.doi.org/10.1371/journal.pone.0047808 PMID: 23094094

41. Zhang HZ, Wu WS, Su F, Sun CM, Jiang MB, Zhang GH, et al. [Valuation on the immunization efficacy on the 23 years who had received plasma-derived HBV vaccine as newborns]. Zhonghua Liu Xing Bing Xue Za Zhi. 2012 Feb;33(2):167–70. Chinese. PMID: 22575145

42. Boccalini S, Pellegrino E, Tiscione E, Pesavento G, Bechini A, Levi M, et al. Seroprevalence of chronic hepatitis B in college students mainly from the rural areas of western China and the immunization efficacy on the 23 years who had received plasma-derived HBV vaccine as newborns]. Zhonghua Liu Xing Bing Xue Za Zhi. 2012 Feb;33(2):207–9. Chinese. PMID: 22575145

43. Griffiths E, Reeve C, Marley M, Hepatitis B notifications in a vaccinated cohort of Aboriginal people in the Kimberley region. Med J Aust. 2014 Sep 15;201(6):343–6. PMID: 25224259

44. Hanna JN, Faoagali JL, Buda PJ, Sheridan JW. Further observations on the immune response to recombinant hepatitis B vaccine after administration to Aboriginal and Torres Strait island children. J Paediatr Child Health. 1997 Feb;33(1):67–70. doi: http://dx.doi.org/10.1111/j.1440-1754.1997.tb00994.x PMID: 9069048

45. FitzSimons D, François G, Hall A, McMahon B, Meheus A, Zanetti A, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine. 2005 Jul 14;23(32):4158–66. doi: http://dx.doi.org/10.1016/j.vaccine.2005.03.017 PMID: 15964484

46. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005 Dec;34(6):1399–408. doi: http://dx.doi.org/10.1093/ije/dyi206 PMID: 16294217